Show simple item record

dc.contributor.authorCarlson, Steven
dc.date2021-11-25T13:35:16.000
dc.date.accessioned2021-11-26T11:56:56Z
dc.date.available2021-11-26T11:56:56Z
dc.date.issued1999-01-01T00:00:00-08:00
dc.identifieryjolt/vol1/iss1/6
dc.identifier.contextkey3916834
dc.identifier.urihttp://hdl.handle.net/20.500.13051/7745
dc.description.abstractAdvances in synthetic chemistry offer pharmaceutical manufacturers a novel means of extending their monopolies over proprietary drugs beyond the 20-year limit of the patent laws. Pharmaceutical companies now have the capability to produce superior drugs by purifying existing drugs into their isomer components. The Food and Drug Administration (FDA) is considering whether to grant new drug status to these purified compounds, and to afford them several years of market exclusivity. This Comment argues that the FDA should not extend such market exclusivity to purified isomers of existing drugs.
dc.titleCOMMENTARY: The Case Against Market Exclusivity for Purified Enantiomers of Approved Drugs
dc.source.journaltitleYale Journal of Law and Technology
refterms.dateFOA2021-11-26T11:56:56Z
dc.identifier.legacycoverpagehttps://digitalcommons.law.yale.edu/yjolt/vol1/iss1/6
dc.identifier.legacyfulltexthttps://digitalcommons.law.yale.edu/cgi/viewcontent.cgi?article=1074&context=yjolt&unstamped=1


Files in this item

Thumbnail
Name:
1YSOLT6.pdf
Size:
172.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record